Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2005 Apr 18;2005(2):CD002828.
doi: 10.1002/14651858.CD002828.pub2.

Corticosteroids for myasthenia gravis

C Schneider-Gold, P Gajdos, K V Toyka, R R Hohlfeld
Meta-Analysis

Corticosteroids for myasthenia gravis

C Schneider-Gold et al. Cochrane Database Syst Rev. .

Abstract

Background: Although widely accepted as an appropriate immunosuppressive therapy, the efficacy of glucocorticosteroid treatment has only rarely been tested in controlled studies.

Objectives: To assess the efficacy of glucocorticosteroids or adrenocorticotrophic hormone (ACTH) medication in autoimmune myasthenia gravis.

Search strategy: We searched the Cochrane Neuromuscular Disease Group Trials Register in July 2004, MEDLINE (from January 1966 to June 2004) and EMBASE (from January 1980 to June 2004). We also checked the bibliographies in reviews and the randomised trials and contacted their authors to identify additional published and unpublished data.

Selection criteria: From the articles identified we selected those open or controlled studies which allowed us to assess the outcome of treated and untreated patients at definite endpoints. Types of studies: quasi-randomised or randomised controlled trials.

Types of participants: patients with myasthenia gravis of all ages and all degrees of severity. Types of interventions: any form of glucocorticosteroids or adrenocorticotrophic hormone treatment. Types of outcome measures:Primary outcome(1) improvement after at least three months in either the weakest muscles or all muscles. Secondary outcomes(1) proportion of patients improved after at least six months(2) proportion of patients in remission(3) number of episodes of worsening during the first six months(4) acetylcholine receptor antibody titres after at least three months of therapy.

Data collection and analysis: Three authors extracted the data from the selected articles and one other checked them.

Main results: A trial of adrenocorticotrophic hormone (43 patients) did not show any advantage compared with placebo for the treatment of ocular myasthenia gravis. Two double-blind trials compared prednisone with placebo for generalised myasthenia gravis. In the first (13 patients), the improvement was slightly greater in the prednisone group at six months. In the second (20 patients) which was a short-term trial, the improvement was significantly greater at two weeks. Two trials compared glucocorticosteroids with azathioprine (41 and 10 patients respectively). In one of these the rate of treatment failure was greater in the prednisone group. In a trial of glucocorticosteroids versus intravenous immunoglobulin (33 patients) no differences in treatment responses were encountered during a treatment period of 14 days. An open trial (39 patients) evaluating different corticosteroid doses revealed a shorter time to improvement in the high-dose group. However only limited evidence can be drawn from the available randomised controlled trials due to numerous and important methodological flaws.

Authors' conclusions: Limited evidence from randomised controlled trials suggests that corticosteroid treatment offers significant short-term benefit in myasthenia gravis compared with placebo. This supports the conclusions of observational studies and expert opinion. Limited evidence from randomised controlled trials does not show any difference in efficacy between corticosteroids and either azathioprine or intravenous immunoglobulin.

PubMed Disclaimer

Conflict of interest statement

KVT and RH were members of the Independent Safety Committee of the study by Schuchardt and co‐workers. PG co‐ordinated a randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis (Gajdos 1993).

Figures

1
1
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD002828

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Bromberg 1997 {published data only}
    1. Bromberg MB, Wald JJ, Forshew DA, Feldman EL, Albers JW. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. Journal of the Neurological Sciences 1997;150(1):59‐62. [PUBMED: 9260858] - PubMed
Gajdos 1993 {published data only}
    1. Myasthenia Gravis Clinical Study Group. A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of a second interim analysis. Myasthenia Gravis Clinical Study Group. Journal of Neurology, Neurosurgery and Psychiatry 1993;56(11):1157‐63. [PUBMED: 8229026] - PMC - PubMed
Howard 1976 {published data only}
    1. Howard FM Jr, Duane DD, Lambert EH, Daube JR. Alternate‐day prednisone: preliminary report of a double‐blind controlled study. Annals of the New York Academy of Sciences 1976;274:596‐607. [PUBMED: 183591] - PubMed
Lindberg 1998 {published data only}
    1. Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurologica Scandinavica 1998;97(6):370‐3. [PUBMED: 9669469] - PubMed
Mount 1964 {published data only}
    1. Mount FW. Corticotropin in treatment of ocular myasthenia; a controlled clinical trial. Archives of Neurology 1964;11:114‐24. [PUBMED: 14159267] - PubMed
Schuchardt 2004 {unpublished data only}
    1. Schuchardt V, Kohler W, Hund E, Scheglmann K, Fleischer E, Jung K, et al. A randomized, controlled trial of high‐dose intravenous immunoglobulin versus methylprednisolone in moderate exacerbations of myasthenia gravis: final analysis after early termination. Data on file.
Zhang 1998 {published data only}
    1. Zhang J, Wu H. Effectiveness of steroid treatment in juvenile myasthenia gravis. Chinese Journal of Pediatrics 1998;36(10):612‐14.

References to studies excluded from this review

Bu 2000 {published data only}
    1. Bu B, Yang M, Xu J, Gao BT, Pan DJ, Cai YX. A prospective study of effectiveness and safety of long‐term prednisone therapy in patients with myasthenia gravis. Chinese Journal of Neurology 2000;33:28‐31.
Gajdos 1983 {published data only}
    1. Gajdos P, Simon N, Rohan‐Chabot P, Raphael JC, Goulon M. Long‐term effects of plasma exchanges in myasthenia. Results of a randomised study. [Effets a long terme des échanges plasmatiques au cours de la myasthénie. Résultats d' une étude randomisée.]. La Presse Médicale 1983;12(15):939‐42. [PUBMED: 6221247] - PubMed
Horstkotte 1992 {published data only}
    1. Horstkotte D, Kutkuhn B, Schultheiss HP, Strauer BE. Prophylactic use of human Ig‐GAM‐preparations in patients on mechanical ventilation undergoing plasmapheresis: results of a randomised study [Prophylaktischer Einsatz humaner Ig‐GAM‐Konzentrate bei Patienten mit Plasmaseparation unter Respiratortherapie: Ergebnisse einer randomisierten Studie.]. Intensivmedizin und Notfallmedizin 1992;29(5):227‐33.
Tindall 1993 {published data only}
    1. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Annals of the New York Academy of Sciences 1993;681:539‐51. [PUBMED: 8357194] - PubMed

Additional references

Arsura 1985
    1. Arsura EL, Brunner NG, Namba T, Grob D. High‐dose intravenous methylprednisolone in myasthenia gravis. Archives of Neurology 1985;42(12):1149‐53. - PubMed
Benatar 2006
    1. Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD005081.pub2] - DOI - PubMed
Besinger 1983
    1. Besinger UA, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, Fateh‐Moghadam A. Myasthenia gravis: Long‐term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983;33(10):1316‐21. [PUBMED: 6684226] - PubMed
Brunner 1972
    1. Brunner NG, Namba T, Grob D. Corticosteroids in the management of severe generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy. Neurology 1972;22(6):603‐10. [PUBMED: 4343255] - PubMed
Chaudhry 2001
    1. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56(1):94‐6. [PUBMED: 11148242] - PubMed
Ciafaloni 2001
    1. Ciafaloni E, Massey JM, Tucker‐Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open‐label pilot study. Neurology 2001;56(1):97‐9. [PUBMED: 11148243] - PubMed
Cosi 1991
    1. Cosi V, Citterio A, Lombardi M, Piccolo G, Romani A, Erbetta A. Effectiveness of steroid treatment in myasthenia gravis: a retrospective study. Acta Neurologica Scandinavica 1991;84(1):33‐9. [PUBMED: 1927259] - PubMed
Evoli 1988
    1. Evoli A, Tonali P, Bartoccioni E, Lo Monaco M. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurologica Scandinavica 1988;77(1):31‐5. [PUBMED: 3354309] - PubMed
Evoli 1992
    1. Evoli A, Batocchi AP, Palmisani MT, Lo Monaco M, Tonali P. Long‐term results of corticosteroid therapy in patients with myasthenia gravis. European Neurology 1992;32(1):37‐43. [PUBMED: 1563453] - PubMed
Gajdos 1997
    1. Gajdos P, Chillet P, Goulon‐Goeau C, Raphael JC. Treatment of myasthenia. Revue Neurologique (Paris) 1997;153(2):91‐105. [PUBMED: 9296120] - PubMed
Gajdos 2002
    1. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD002275] - DOI - PMC - PubMed
Gajdos 2008
    1. Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD002277.pub3] - DOI - PubMed
Genkins 1971
    1. Genkins G, Kornfeld P, Ossermann KE, Namba T, Grob D, Brunner NG. The use of ACTH and corticosteroids in myasthenia gravis. Annals of the New York Academy of Sciences 1971;183:369‐74. [PUBMED: 4330763] - PubMed
Grob 1981
    1. Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Annals of the New York Academy of Sciences 1981;377:652‐69. [PUBMED: 6951490] - PubMed
Hart 2007
    1. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005224.pub2] - DOI - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1[updated September 2008]. www.cochrane‐handbook.org.
Hohlfeld 2003
    1. Hohlfeld R, Melms A, Schneider C, Toyka KV, Drachman DB. Therapy of myasthenia gravis and myasthenic syndromes. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C editor(s). Neurological disorders ‐ course and treatment. 2nd Edition. Amsterdam: Elsevier, 2003:1341‐1362.
Jaretzki 2000
    1. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis. Recommendations for clinical research standards. Task force of the Medical Scientific Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55(1):16‐23. [PUBMED: 10891897] - PubMed
Lewis 1995
    1. Lewis RA, Selwa JF, Lisak RP. Myasthenia gravis: immunological mechanisms and immunotherapy. Neurology 1995;37((S1)):51‐62. [PUBMED: 8968217] - PubMed
Mehndiratta 2011
    1. Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD006986.pub2] - DOI - PubMed
Nagane 2005
    1. Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y. Efficacy of low dose FK506 in the treatment of myasthenia gravis. A randomized pilot study. European Neurology 2005;53:146‐50. [PUBMED: 15900097] - PubMed
Oosterhuis 1997
    1. Oosterhuis HJGH. Myasthenia gravis. Groningen: Groningen Neurological Press, 1997:127.
Osserman 1971
    1. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty year experience in over 1200 patients. The Mount Sinai Journal of Medicine, New York 1971;38(6):479‐537. [PUBMED: 4941403] - PubMed
Palace 1998
    1. Palace J, Newsom‐Davis J, Lecky B. A randomized double‐ blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50(6):1778‐83. [PUBMED: 9633727] - PubMed
Panegyres 1993
    1. Panegyres PK, Squier M, Mills KR, Newsom‐Davis J. Acute myopathy associated with large parenteral dose of corticosteroids in myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry 1993;56(6):702‐4. [PUBMED: 8509789] - PMC - PubMed
Pascuzzi 1984
    1. Pascuzzi RM, Coslett HB, Johns TR. Long‐term corticosteroid treatment of myasthenia gravis: report of 116 patients. Annals of Neurology 1984;15(3):291‐8. [PUBMED: 6721451] - PubMed
Richman 2003
    1. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003;61(12):1652‐61. [PUBMED: 14694025] - PubMed
Sanders 2008
    1. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, Baets MH, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71(6):400‐6. [PUBMED: 18434638] - PubMed
Schneider 2001
    1. Schneider C, Gold R, Reiners K, Toyka KV. Mycophenolate mofetil in the therapy of severe myasthenia gravis. European Neurology 2001;46(2):79‐82. [PUBMED: 11528156] - PubMed
Seybold 1974
    1. Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. New England Journal of Medicine 1974;290(2):81‐4. [PUBMED: 4808454] - PubMed
Sghirlanzoni 1984
    1. Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F. Myasthenia gravis: prolonged treatment with steroids. Neurology 1984;34(2):170‐4. [PUBMED: 6538004] - PubMed
Simon 1935
    1. Simon HE. Myasthenia gravis: Effect of treatment with anterior pituitary extract. JAMA 1935;104:2065‐6.
Soffler 1948
    1. Soffler LJ, Gabrilove JL, Laqueur HP, Volterra M, Jacobs MD, Sussmann ML. The effects of anterior pituitary adrenocorticotrophic hormone (ACTH) in myasthenia gravis with tumor of the thymus. Journal of Mount Sinai Hospital 1948;15:78. - PubMed
Sommer 1997
    1. Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, et al. Ocular myasthenia gravis: response to long term immunosuppressive treatment. Journal of Neurology, Neurosurgery and Psychiatry 1997;62(2):156‐62. [PUBMED: 9048716] - PMC - PubMed
Thomas 1997
    1. Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, et al. Myasthenic crisis : clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997;48(5):1253‐60. [PUBMED: 9153452] - PubMed
Tindall 1987
    1. Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double blind, randomized, placebo‐controlled trial of cyclosporine in myasthenia gravis. New England Journal of Medicine 1987;316(12):719‐24. [PUBMED: 3547126] - PubMed
Vincent 2003
    1. Vincent A, Bowen J, Newsom‐Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies and their targets. Lancet Neurology 2003;2(2):99‐106. [PUBMED: 12849266] - PubMed
von Reis 1966
    1. Reis G, Liljestrand A, Matell G. Treatment of severe myasthenia gravis with large doses of ACTH. Annals of the New York Academy of Sciences 1966;135(1):409‐16. [PUBMED: 4287550] - PubMed
Warmolts 1971
    1. Warmolts JR, Engel WK. Benefit from alternate‐day prednisone in myasthenia gravis. Neurology 1971;21:412‐7. - PubMed

MeSH terms